Pneumococcal Vaccines

Publisher Website
Google Scholar
Abstract
A comprehensive explanation of the extraordinary public health benefits of pneumococcal conjugate vaccines The development of protein conjugate vaccines against pneumococcal disease is arguably the greatest public health achievement of the new millennium. This book describes the development of the vaccines, their remarkable impact on respiratory and other pneumococcal infections, and the vaccines’ wider impact on public health. Acute respiratory infections due to pneumococci are the leading vaccine-preventable cause of death. The first pneumococcal conjugate vaccine was licensed seven years ago in the United States and is now in general use worldwide. While the vaccine’s dramatic impact on the target population was anticipated, the magnitude of herd immunity provided to unimmunized individuals was not. This benefit has enormously enhanced the public health impact of the vaccine. With 28 chapters contributed by the world’s leading experts, this book summarizes the latest findings on the effects of pneumococcal conjugate vaccine. It includes chapters on epidemiology, immunologic mechanisms, conjugation methods, antibiotic resistance, PCV immunogenicity in healthy and high-risk individuals, otitis media, and direct and indirect protective effects. For professionals in academia, public health, government, or industry, this book summarizes the current knowledge on pneumococcal vaccines with particular emphasis on the years after the introduction of the conjugate vaccine. Hardcover, 449 pages, illustrations, index.

This publication has 0 references indexed in Scilit: